TNM Trial: Upfront Docetaxel [T] and Alternating iv and Oral Vinorelbine [N] Followed, by Either Maintenance Oral Vinorelbine, or Observation for Advanced Breast Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 11 Feb 2019
Price : $35 *
At a glance
- Drugs Vinorelbine (Primary) ; Vinorelbine (Primary) ; Docetaxel
- Indications Adenocarcinoma; Advanced breast cancer
- Focus Therapeutic Use
- Acronyms TNM Trial
- 07 Feb 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 07 Feb 2017 Planned primary completion date changed from 1 Jun 2016 to 1 Jun 2017.
- 07 Feb 2017 Status changed from recruiting to active, no longer recruiting.